 
CLINICAL STUDY PROTOCOL
Protocol Title:   A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety,  
Tolerability, Efficacy, and Pharm acokinetics of Orally Administ ered 
TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic 
Non-Alcoholic Steatohepatitis (NASH) 
Protocol Number:  TERN101-2001 
Protocol Version:  Amendment 1 
Version Date:  22 May 2020 
Supersedes:  Original; 26 February 2020 
Compound:  TERN-101 
Study Phase:  2a 
Sponsor Name:  Terns, Inc.  
Legal Registered Address:  1065 E. Hillsdale Blvd. Suite 100 Foster City, California 94404 
Regulatory Agency Identifier Number(s)  
US FDA IND:    
CONFIDENTIAL 
This document contains confiden tial information, which should n ot be copied, referred to, 
released or published without wr itten approval from Terns, Inc.  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 6 of 82   1. Protocol Summary 
1.1. Synopsis 
Protocol Title:  
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Pa rallel-Group, Phase 2a 
Clinical Trial to Evaluate th e Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally 
Administered TERN-101 Tablets in Adult Patients with Presumed N on-Cirrhotic Non-Alcoholic 
Steatohepatitis (NASH)  
  
 
 
 
 
 
 
 
 
 
Objectives:  
Primary Objective
:  
x To evaluate safety and toler ability of 3 doses of orally admini stered TERN-101 versus 
placebo for 12 weeks in non-cirrhotic  presumed NASH patients, w ith clinical or 
histological NASH diagnosis   
Secondary Objectives: 
x To evaluate the change in alanine aminotransferase (ALT) with 3  doses of TERN-101 for 
12 weeks versus placebo in non-cirr hotic presumed NASH patients   
x To evaluate the pharmacokine tics (PK) of 3 doses of TERN-101 in  non-cirrhotic 
presumed NASH patients  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 7 of 82   Exploratory Objectives:  
x To assess the effect of 3 doses  of TERN-101 on liver fat conten t (LFC) and additional 
indicators of NASH disease activity 
x To evaluate FXR target eng agement of 3 doses of TERN-101 in non-cirrhotic presumed 
NASH patients  
x To evaluate the effect of 3 dos es of TERN-101 on biomarkers of liver fibrosis  
Endpoints:  
Primary Endpoint:  
x Overall safety assessed by adver se events (AEs) including treat ment emergent AEs 
(TEAEs), and proportion  of patients with trea tment-emergent cli nical safety laboratory 
abnormalities 
Secondary Endpoints:  
x Percent change from baseline in ALT levels at 12 weeks 
x Plasma PK for  TERN-101  
Exploratory Endpoints:  
x Change from baseline in LFC by ma gnetic resonance imaging-pr oton density fat fraction 
(MRI-PDFF)  
x Change from baseline in gamma-g lutamyl transpeptidase (GGT) 
x Change from baseline in aspar tate aminotransferase (AST)  
x Change from baseline in FGF-19  
x Change from baseline in 7- Ä®-C4 
x Change from baseline in NAS H/fibrosis blood biomarkers  
x  
Overall Design:   
This study is a multicenter, randomized, double-blind, placebo- controlled, para llel-group study. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 8 of 82   Approximately 96 clinically or histologically diagnosed adult n on-cirrhotic presumed NASH 
patients who meet study eligibilit y criteria will  be enrolled a nd randomized at an overall ratio of 
1:1:1:1 into 4 groups receiving 5 mg (n = 24), 10 mg (n = 24), 15 mg (n = 24) TERN-101 tablets, 
or matching placebo (n = 24) orally once daily.  
Of the 96 patients randomized, 24 pa tients will ta ke part in an  intensive PK and 
pharmacodynamic (PD) collection aft er the first dose and after the last dose of study drug. This 
includes 6 patients at each TERN-101 dose level, and 6 patients  in the placebo group. Patients 
who are not participating in the  PK/PD sub-study will have trou gh PK/PD sampling only.  
The total duration of study par ticipation will be  approximately 24 weeks, consisting of an 8-
week Screening Period, a 12-week T reatment Period and a 4-week Follow-up Period.  
Disclosure Statement:  This is a parallel- group treatment study.  
Number of Patients: Approximately 96 patients will be randomly a ssigned to treatmen t with TERN-101 tablet or 
matching placebo. 
Patients who are randomized but do not receive study drug for a ny reason may be replaced.  
Study Centers Planned:  Approximately 40 centers i n the United States. 
Intervention Groups and Duration: 
The total study duration will be a pproximately 24 weeks, consis ting of an 8-week Screening 
Period, a 12-week Treatment Peri od and a 4-week Follow-up Perio d.  
Screening Period 
The 8-week Screening Period in itiates upon signing an Informed Consent, at which point 
eligibility criteria will be reviewed. Each eligible patient wi ll be scheduled for Week 0/Day 1.  
Treatment Period 
The 12-week double-blind, randomi zed Treatment Period will init iate at Week 0/Day 1 after 
confirming eligibility. The bli nded study drug (TERN-101 tablet or placebo) will be orally 
administered once daily in the  morning, without regard to food.  
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
CONFIDENTIAL Page 9 of 82  Patients will return to the site at Weeks 2, 4, 6, 8, and 12 for safety and laboratory assessments. 
Study drug will be dispensed at We ek 0/Day 1, Week 4, and Week 8. Week 12 is the last day of 
treatment.  
Intensive PK/PD sampling will be  performed in 24 patients parti cipating in the PK/PD sub-study
after the first dose (Week 0/Da y 1) and after the last dose of study drug (Week 12).  
Imaging (MRI-PDFF) will be com pleted at Week 0, Week 6, and Wee k 12. An MRI is 
performed at early terminati on (ET) only if not done within the  prior 4 weeks, and the patient has 
had at least 4 weeks of dosing.   
Follow-up Period 
All patients will re turn to site for follow up safety assessments at Week 16. 
If study drug is permanently disc ontinued for any reason outlined in Section 7 , the patient will be 
encouraged to remain in the st udy to be evaluated during the Fo llow-Up Period. See the 
Schedule of Ac tivities for data  to be collected at the time of discontinuation of study drug and 
follow-up, and for any further evalu ations that need to be comp leted. 
1.2. Schema
Abbreviations: MRI-PDFF = magnetic resonance imaging proton density fat fraction; PK/PD = 
pharmacokinetics/pharmacodynamics; QD = once a day

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
  
 
CONFIDENTIAL Page 10 of 82   1.3. Schedule of Activities (SoA) 
 Screening Treatment Periode  Follow-
Upb  ETa N otes 
Visit Screening Week 
0  Week 
2 Week 
4 Week 
6 Week 
8 Week 
12 Week 
16   
Study Day -56 to Day 
-1 Day 1 15 29 43 57 85 113  Visit windows post randomization through Week 12: Â± 
3 days from the specified study day. Visit window 
Week 16: -1 week /+2 days from the specified study 
day. 
Procedures  
Written Informed Consent X         Written informed consent may be obtained via telephone in accordance with Section 10.1.2 . 
Screening may be initiated via telephone to avoid a visit to the site, if the patient is disqualified based on 
medical history. 
Patient Fasting X X  X  X X X X Patients must be in fasted state for at least 8 hours 
prior to blood collection and treatment administration where applicable. 
Randomization   X         
Review 
Inclusion and 
Exclusion 
Criteria X X        Recheck clinical status before randomization and first 
dose of study drug.  
Demographics X         Includes age, sex, and race/ethnicity.  
Height and Weight X X  X X X X X X Height and weight are collected at Screening and will be used to calculate BMI for eligibility. Waist circumference is also measured at Screening. Only 
weight is collected Week 0, 4 , 6, 8, 12, 16, and ET.    
Medical history  X         Includes details of illnesses and allergies, date(s) of 
onset, whether condition(s) is currently ongoing, and 
medication history, including alcohol use. 
Physical Examination X X X X X X X X X A complete physical examination will be performed at Screening and Week 16. A targeted physical examination will be performed at all other visits. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
  
 
CONFIDENTIAL Page 15 of 82   f In the event of symptoms suggestive of COVID-19, ad hoc testing (including molecular test such as PCR or viral antigen serolog y, and/or antibody testing, 
once available via the central laboratory), may be completed at Investigatorâ€™s discretion. 
g If a patient is required to be quarantined due to active infection of COVID-19 or exposure to COVID-19, or is otherwise unab le to visit the site due COVID-19, 
study drug may be mailed to the patient or made available via a nother appropriate mechanism (ie, curbside pickup, etc.). 
Abbreviations:  AE = adverse event; ALT = alanine transaminase; AST = aspartat e transaminase; BMI = body mass index; CK18 = cytokeratin-18; C OVID-19 = 
coronavirus disease 2019; CTCAE = common terminology criteria f or adverse events; ECG = electrocardiogram; ET = early terminat ion; eGFR = estimated glomerular 
filtration rate; FSH = follicle stimulating hormone; HA = hyalu ronic acid; HbA1c = hemoglobin A1c; HBsAG = hepatitis B surface  antigen; HCV = hepatitis C virus; 
HIV = human immunodeficiency virus; hsCRP = high sensitivity C-reactive protein; INR = international normalized ratio; IWRS = interactive web response system; 
MRI = magnetic resonance imaging; NCI =  National Cancer Instit ute; PCR = polymerase chain reaction; PD = pharmacodynamics; PI IINP = Procollagen III N-Terminal 
Propeptide; PK = pharmacokinetics; Pro-C3 = released N-terminal  pro-peptide of type III collagen; SAE = serious adverse event; TIMP-1 = tissue inhibitor of 
metalloproteinases-1; ULN = upper limit of normal; WOCBP = wome n of childbearing potential.
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 16 of 82  2. Introduction 
2.1. Overview of Nonalcoholic Steatohe patitis (NASH) and Unmet Need  
This study is a randomized, doubl e-blind, placebo-controlled, p arallel-group, P hase 2a study to 
evaluate the safety, tolerabi lity, efficacy, and PK of various doses of TERN-101 in non-cirrhotic 
presumed NASH patients. TERN- 101 is a highly selective and pote nt small molecule agonist of 
FXR in development for the trea tment of patients with NASH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Background 
2.2.1. TERN-101 and FXR Agonists f or Treatment of NASH 
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 17 of 82   
 
 
 
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
TERN-101 is a non-steroidal, synthe tic small molecule  and is 
formulated for oral administra tion in capsule or tablet form. T ERN-101 is a potent FXR agonist. 
As a selective and potent nonstero idal, non-bile acid FXR agonist, TERN-101 may offer a 
unique safety and efficacy profile  to benefit the NASH patient population. As summarized 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 18 of 82  below, nonclinical studies and Pha se 1 clinical studies of TERN -101 support its potential utility 
as a disease-modifying t reatment for NASH. 
2.2.2. Summary of Nonclinical Studies 
 
 
 
 
 
  
In mouse  NASH models, TERN-101 inhibited 7- DC4 and significantly reduced NAFLD 
activity score (NAS) and liver fib rosis area. NAS was markedly reduced by all doses of TERN-
101 tested ( Figure 1, left panel) with an 80% reduc tion from baseline at 100 mg/kg (mpk). 
Steatosis was reduced to healthy control (lean mice) levels at 30 mpk ( Figure 2 , left), and 
hepatocellular ballooning was red uced to healthy control levels  at 100 mpk ( Figure 2 , middle).  
Hepatic inflamma tion was also reduced in TERN-101 treated mice (Figure 2 , right). The 
improvement in liver histology c orrelated with a reduction in liver triglycerides, serum lipids and 
the liver-related enzymes ALT and AST. These results indicate p otent FXR agonist activity and 
support that TERN-101 has the potential for use in the treatmen t of NASH. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
CONFIDENTIAL Page 19 of 82  Figure 1.  TERN-101 Reduces NAS and Liver Fibrosis in a NASH Mo use Model   
Obese mice fed a high-fat diet and chronically treated with CCl 4 were dosed with varying amounts of TERN-
101 for 28 days. Liver tissue was isolated at end of study and analyzed by histopathology for NAFLD Activity 
Score (NAS, combination of liver steatosis, ballooning and infl ammation determined by hematoxylin and eosin 
staining) (left) or liver fibrosi s area (sirius red staining) ( right).  Data are presented as Mean Â± SEM (n=7 for 
TERN-101/100 mpk, n=8 for all other groups; ***pã¸º 0.001, **p ã¸º0.01, *p ã¸º0.05 vs NASH Control 
(Vehicle); statistics determined by one-way ANOVA followed by T ukey). 
Figure 2.  TERN-101 Reduces Liver St eatosis, Ballooning, and In flammation in a 
NASH Mouse Model  
Obese mice fed a high-fat diet and chronically treated with CCl 4 were dosed with varying amounts of TERN-
101 for 28 days. Liver tissue was isolated at end of study and analyzed by histopathology for liver steatosis 
(left), ballooning (middle) and inflammation (right) using H&E staining.  Data are presented as Mean Â± SEM 
(n=7 for TERN-101/100 mpk, n=8 for all other groups; ***p ã¸º0.001, **p ã¸º0.01, *p ã¸º0.05 vs NASH Control 
(Vehicle); statistics determined by one-way ANOVA followed by T ukey). 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 22 of 82  TERN-101 5-mg tablet and at 1.52 hours for TERN-101 25-mg tablet. Transient increases in 
FGF-19 concentrations and dose-dependent decreases in 7- Ä®-C4 concentrations were observed 
after single doses of TERN-101 tab lets. Administration of TERN- 101 (5 mg) tablet with food 
delayed the time of maximal plasma concentrations (from ~1 hour  fasted to ~4 hours fed) but did 
not result in significant diffe rences in exposure as assessed b y AUC.  
 
 
 
 
Safety findings from the 4 clini cal studies showed that TERN-10 1 was well-tole rated overall. 
AEs were predominantly mild and t ransient. The predefined maxim um tolerated dose was not 
reached in any study. The overall AE incidence was generally ba lanced between dose groups. 
Following multiple doses of TERN-101 capsules of up to 400 mg, no TEAEs were attributable to 
TERN-101 on the basis of frequen cy, dose-relationship, or expec ted pharmacology. Pruritus was 
not reported by any of the 119 huma n subjects who have received  TERN-101 to date.  
 
 
 
 
  No 
transaminase elevations > 1.5 t imes upper limit of normal were observed in the subsequent 
completed repeat dose study (TERN 101-US-A101) 
 or Study TERN101-US-A104). In the 2 completed repeat do se Phase 1 TERN-101 
studies, no consistent trends in c hanges from baseline in LDL c holesterol were observed with 
TERN-101. In the recently complete d Phase 1 study TERN101-US-A1 04, there was no 
consistent pattern of L DL change on-study; several subjects had  elevated levels prior to dosing, 
and LDL remained at overal l similar levels on-study. 
Additional information on availa ble TERN-101 clinical study res ults, including clinical 
pharmacology and dose-selection cons iderations, is provided in the Investigatorâ€™s Brochure. 
2.3. Benefit/Risk Assessment 
 
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 23 of 82   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
The protocol has be en designed to minimize the risk to patients . Patients will be monitored to 
detect AEs during the study and w ill be followed a ppropriately to ensure resolution of AEs. 
Standard hematology, c hemistry, and lipid levels will be obtain ed and monitored for 
abnormalities in a  blinded fashion.  
Overall, based on past experience  of clinical studies of TERN-1 01 in healthy volunteers, the 
benefit/risk assessmen t is considered to be positive for patien ts to be enrolled in this study. More 
detailed information about the known and expe cted benefits and risks and reasonably expected 
adverse events of TERN-101 ma y be found in the Investigatorâ€™s B rochure. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 24 of 82   3. Objectives and Endpoints 
Objectives:  
Primary Objective:  
x To evaluate safety and tolerability of 3 doses of orally admini stered TERN-101 versus 
placebo for 12 weeks in non-cirrhotic presumed NASH patients, with clinical or 
histological NASH diagnosis   
Secondary Objectives: 
x To evaluate the change in ALT with 3 doses of TERN-101 for 12 w eeks versus placebo in 
non-cirrhotic presumed NASH patients 
x To evaluate the PK of 3 doses of TERN-101 in non-cirrhotic pres umed NASH patients 
Exploratory Objectives:  
x To assess the effect of 3 doses of TERN-101 on LFC and addition al indicators of NASH 
disease activity  
x To evaluate FXR target engagement of 3 doses of TERN-101 in non -cirrhotic presumed 
NASH patients 
x To evaluate the effect of 3 dos es of TERN-101 on biomarkers of liver fibrosis  
Endpoints:  
Primary Endpoint:  
x Overall safety assessed by AEs including TEAEs, and proportion of patients with 
treatment-emergent clinical safety laboratory abnormalities 
Secondary Endpoints:  
x Percent change from baseline in ALT levels at 12 weeks 
x Plasma PK for  TERN-101  
Exploratory Endpoints:  
x Change from baseline in LFC by MRI-PDFF  
x Change from baseline in GGT  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 25 of 82   x Change from baseline in AST  
x Change from baseline in FGF-19  
x Change from baseline in 7- Ä®-C4  
x Change from baseline in NAS H/fibrosis blood biomarkers  
  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 26 of 82   4. Study Design 
4.1. Overall Design 
This study is a multicenter, randomized, double-blind, placebo- controlled, para llel-group study. 
Approximately 96 clinically or histologically diagnosed adult n on-cirrhotic presumed NASH 
patients who meet study eligibilit y criteria will  be enrolled a nd randomized at an overall ratio of 
1:1:1:1 into 4 groups receiving 5 mg (n = 24), 10 mg (n = 24), 15 mg (n = 24) TERN-101 tablet 
or matching placebo (n = 24) orally once daily.  
Of the 96 patients randomized, 24 pa tients will ta ke part in an  intensive PK and PD collection 
after the first dose and afte r the last dose of study drug. Thi s includes 6 patients at each 
TERN-101 dose level, and 6 patients in the placebo group. Patie nts who are not participating in 
the PK/PD sub-study will have  trough PK/PD sampling only.  
The total study duration will be a pproximately 24 weeks, consis ting of an 8-week Screening 
Period, a 12-week Treatment Per iod and a 4-week Follow-up Perio d.  
4.2. Scientific Rationale for Study Design 
The study will enroll male and fem ale patients with non-cirrhotic presumed NASH in order to 
obtain evidence of safety, pre liminary efficacy, PK, and PD of 3 dose levels of TERN-101. The 
multiple-dose design of this study is randomized and double-blinded to minimize bias and to 
enable efficient evaluation of  different dose levels. The place bo control is included to facilitate 
identification of effects relate d to administration of TERN-101  rather than the study procedures, 
disease, or situation. The st udy duration will allow characteri zation of the safety and tolerability 
of TERN-101 with 12 weeks of dosing a s well as initial assessme nt of effect of TERN-101 on 
efficacy parameters  in a NASH population. 
4.3. Justification for Dose 
Based on PK results from TERN 101-US-A104 Phase 1 study in healt hy subjects, the tablet 
formulation of TERN-101 was dose linear in the range of 5 mg to  25 mg, with AUC 0-t of  
475 (Â±161) ng*hr/mL and 2890 (Â± 720) ng*hr/mL for 5 and 25 mg ta blets, respectively. 
 
 
Evidence of FXR target enga gement was seen for doses ranged from 5 mg to 
25 mg tablets of TERN-101 (see Section 2.2.3). The doses selected for this study of 5 mg, 
10 mg, and 15 mg TERN-101 tablets are  expected to achieve FXR target engagement and will 
allow for characterization of the  safety and efficacy of TERN-1 01 across these dose levels. 
There was no significant impact  of food intake on TERN-101 PK based on results from 
Study TERN101-US-A104, thus TERN- 101 can be dosed without regar d to food intake.  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 27 of 82   5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exem ptions, is not permitted. 
5.1. Inclusion Criteria 
Patients are eligible to be inc luded in the study only if all o f the following criteria apply: 
1. Must be 18 to 75 years of age inclu sive, at the time of signing  the informed consent 
 
 
 
3. 2YHUZHLJKWRUREHVHZLWKD ERG\PDVVLQGH[%0,Â•NJP2 
4. NASH by clinical diagnosis or biopsy as follows:  
a. For clinical diagnosis:  
i. Step 1: Liver stiffness measur ed by transient e lastography of 7.6 - 21 kPa 
and controlled attenua tion parameter (CAP) > 300 dB/m within 3 months 
prior to Screening (if results a vailable withi n this timeframe,  assessment 
does not need to be repeated at Screening).  
ii. Step 2: Patients mee ting these and all othe r eligibility criter ia will undergo 
MRI-3'))DQGPXVWKDYHOLYHUIDWFRQWHQWÂ•IRU randomization.  
b. For biopsy diagnosis:  
i. Step 1: Fibrotic NASH (NASH CRN  F1, F2, or F3) without cirrhosi s 
diagnosed by biopsy within 2 years  prior to randomization, with no 
subsequent treatment for NASH and stable weight (< 5% weight lo ss) 
since the time of the biopsy. Results from a previous study bio psy are 
permissible if drug was deeme d non-therapeutic or patient received 
placebo.  
ii. Step 2: Patients mee ting these and all othe r eligibility criter ia will undergo 
MRI-3'))DQGPXVWKDYHOLYHUIDWFRQWHQWÂ•IRU randomization. 
5. All patients must have: 
x ALT Â• 43 ,8/IRUPHQDQGÂ• 28 IU/L for women 
x MRI PDFF lLYHUIDWFRQWHQWÂ•  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 28 of 82   6. Capable of giving signed inform ed consent as described in Section 10.1.2, which includes 
compliance with the requirement s and restrictions listed in the  informed consent form 
(ICF) and in this protocol 
5.2. Exclusion Criteria  
Patients are excluded from the study if any of the following cr iteria apply: 
Medical Conditions 
1. History or clinical evidence of  chronic liver diseases other th an NAFLD including but not 
limited to: 
x Active hepatitis B defi ned as positive Hep B surface antigen at  screening  
x Active hepatitis C defi ned as positive Hep C virus (HCV) antibo dy (anti-HCV) 
and HCV ribonucleic acid (RNA). P atients with anti-HCV but negative HCV 
RNA will be eligible f or participation if HCV RNA has been nega tive for at least 
1 year.  
x Autoimmune liver disease 
x Primary biliary cirrhosis 
x Primary sclerosing cholangitis 
x Wilsonâ€™s disease 
x Gilbertâ€™s syndrome if direct b ilirubin is above 0.3 mg/dL or ev idence of active 
hemolysis  
x Hemochromatosis or other iron overload  
x Alpha-1-antitrypsin deficiency 
x Alcoholic liver disease 
x Prior known drug-induce d hepatotoxicity 
x Known bile duct obstruction 
x Suspected or proven liver cancer  
2. History or clinical evidence of cirrhosis, hepatic decompensati on or other severe liver 
impairment, including ascites , hepatic encephalopathy, and vari ceal bleeding 
3. History of liver transplant, or c urrent placement on a liver tr ansplant list 
4. Total bilirubin > 1.2 mg/dL. Note  patients with Gilbert syndrom e may be enrolled if total 
bilirubin < 2 mg/dL and direct bilirubin Â” 0.3 mg/dL.  
5. Albumin < 3.5 g/dL  
6. INR > 1.1  
7. ALT or AST > 5 Ã— ULN 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 29 of 82   8. Unstable elevated ALT or AST. Pa tients with ALT or AST > 60 IU/ L must have 
evidence of a stable ALT/AST over at least a 2-week time period  prior to randomization 
   
 
  
  
 
 
 
  
9. ALP > 156 IU/L 
10. Platelet count < 150,000 /mm3 
11. eGFR < 60 mL/min/1.73m2  
12. Weight loss of > 5% total body wei ght within 3 months prior to Screening 
13. History of a maligna ncy within 2 years of screening, with the f ollowing exceptions:  
a) Adequately treated carci noma in situ of the cervix 
b) Adequately treated basal or squa mous cell cancer or other local ized non-melanoma 
skin cancer  
14. Uncontrolled diabetes with HbA1c  > 9.5%.  
 
 
15. Unstable cardiovascular (CV) dis ease defined as myocardial infa rction, unstable angina, 
percutaneous intervention, cor onary artery bypass graft, or str oke within 6 months prior 
to randomization 
16. 8QFRQWUROOHGK\SHUOLSLGHPLDGHILQHGDVIDVWLQJ/'/Â• 50 mg/dL despite treatment or 
total triglycerides > 300 mg/dL  
17. QTc > 450 ms for males, > 470 ms for females 
18. Known allergy to study drug  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 30 of 82    
  
20. Average weekly alcohol consump tion of > 21 standard drinks for males and > 14 
standard drinks for females over a period of more than 3 consec utive months in the year 
prior to Screening. Remote history of alcoholism with abstinenc e > 12 months prior to 
Screening and no history of alcoholic liver di sease is permissible.  
Note: A standard drink is de fined as 12 oz (360 ml) beer, 1.5 o z (45 ml) liquor, or 5 
oz (150 ml) wine.  
21. Illicit substance/chemical abus e in the 12 months prior to Scre ening 
22. Cannabis use (tetrahydrocannabinol  [THC] and cannabidiol [CBD])  within 14 days of 
randomization 
23. Unwilling to abstain from excessive alcohol use (defined in #20  above), cannabis use, 
and illicit substance use during study participation 
24. Contraindications or inability t o complete MRI scanning (ie, we ight restrictions, presence 
of permanent pacemaker, impla nted cardiac devices, etc.) 
25. Positive for human immunodefici ency virus (HIV) infection 
26. Laboratory or clinical evidence  of current infection with Sever e Acute Respiratory 
Syndrome Coronavirus 2 (S ARS-CoV-2), i.e. COVID-19 
27. Presence of any condition that could, in the opinion of the inv estigator, compromise the 
patientâ€™s ability to par ticipate in the study 
Prior or Anticipated Therapy  
28. Treatment with OCA, other inve stigational FXR agonists, SLRJOLWD]RQHRURWKHU33$5È–
agonists, or high-dose vitamin E  (> 400 IU/day) within 3 months  prior to Screening. 
Patients treated with vitamin E Â”,8GD\PXVWKDYHEHHQRQVWDEOHGRVHIRUDWOHDVW 3 
months prior to Screening and s hould remain on the same dose du ring study. Patients 
treated with GLP-1 analogues, D PP-4 inhibitors, and SGLT2 inhib itors must have been 
on a stable dose for at least  3 months prior to Screening and s hould remain on the same 
dose during study.  
29. Use of medications potentiall y impacting steatohepatitis within  3 months of 
randomization, including but not limited to systemic  corticoste roids (prednisone 
equivalent of > 10 mg/day for > 2 weeks), a miodarone, tamoxifen  and methotrexate) 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 31 of 82   30. Initiation of the following medi cations within 3 months of rand omization; or dose 
adjustment expected duri ng study participation:   
x Statins or PCSK9 inhibitors 
x Metformin and other an tidiabetic drugs (mu st have been on stable dose for at least 
2 months before randomization). N ote: GLP-1 analogues, DPP-4 in hibitors, and 
SGLT2 inhibitors  addressed above. 
x Hormonal contraceptives 
 
 
 
Prior Clinical Study Experience 
32. Participation in another clinical trial within 3 months prior t o randomizatio n. 
 
 
 
  
 
 
  
 
 
5.3.2.  Meals and Dietary Restrictions 
Patients should arrive a t the clinic fasting for assessments and dosing as def
ined in the Schedule 
of Activities ( Section 1.3 ). This includes at least an 8- hour fast prior to the visit, du ring which 
food and drink is restricted. Wat er is allowed ad libitum.  
Patients participating in the  PK/PD Sub-Study at (Week 0/Day 1)  and Week 12 should arrive at 
the clinic fasting (an 8-hour fas t prior to the visit) and rest rict food and drink until 2 hours post-
dose. Food and drink may resume af ter this timepoint. Patients participating in the PK/PD Sub-
Study do not need to be fasting for blood collection at 24, 48,  or 72 hours post-dose. 
 
  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 32 of 82   5.3.3. Alcohol, Cannabis, and Illicit Drug Use 
Patients must agree to not consum e > 21 standard drinks per wee k for males and > 14 standard 
drinks per week for females. A standard drink is defined as 12 oz (360 ml) beer, 1.5 oz (45 ml) 
liquor, or 5 oz (150 ml) wine.  
Patients must abstain from TH C (cannabis) and illicit drug use during study participation.  
Patients must abstain from CBD  use during study participation. Short term topical CBD use (< 
14 days) is acceptable.   
5.4. Screen Failures 
Screen failures are defined as  patients who consent to participate in the clinical study but are not 
subsequently randomized. A minima l set of screen failure inform ation is required and will be 
documented to ensure transparen t reporting of screen failure pa tients to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demog raphy, screen failure details, 
eligibility criteria , and any serious adverse event (SAE). 
Any patient who screen fails due t o SARS-CoV-2 testing or clinical status may re-screen at the 
discretion of the Investigator on ce SARS-CoV-2 infection has re solved. Any other requests for 
re-screening must be disc ussed with the Sponsor.  
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 34 of 82     
 
 
 
 
 
 
 
 
 
6.4. Measures to Minimize Bias: Randomization and Blinding 
Patients will be ra ndomized to TERN-101 or placebo using an Int eractive Web Response System 
(IWRS). Before the study is in itiated, the log-i n information a nd directions for the IWRS will be 
provided to each site.  
Approximately 96 patients will be randomized at an overall rati o of 1:1:1:1 into 4 groups 
receiving 5 mg (n = 24), 10 mg ( n = 24), 15 mg (n = 24) TERN-10 1 tablet, or matching placebo 
(n = 24). Randomization will en sure 6 patients at each TERN-101  dose level and 6 patients in the 
placebo group are assigned t o the PK/PD sub-study. 
Investigators, patients, all study personnel, and the Sponsor w ill remain blinded t o each patientâ€™s 
assigned dose group throughout the course of the study. Study d rug will be dispensed at the 
study visits as summarized in Sche dule of Activities. Returned study drug should not be re-
dispensed to patients.  
6.4.1. Unblinding  
Treatment assignment may be unbli nded if knowing the patientâ€™s treatment assignment would 
affect immediate medical management of the patient. The IWRS wi ll be programmed with blind-
breaking instructions. In case of an emergency, the Investigato r has the sole responsibility for 
determining if unblinding of a patientâ€™s intervention assignmen t is warranted. Pa tient safety must 
always be the first considera tion in making such a determinatio n. If the Investigator decides that 
unblinding is warranted, the Inve stigator should make every eff ort to contact the Sponsor prior to 
unblinding a patientâ€™s interven tion assignment unless this coul d delay emergenc y treatment of 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 35 of 82   the patient. If a pa tientâ€™s intervention assignment is unblinde d, the Sponsor must be notified 
within 24 hours after breaking t he blind. The date and reason t hat the blind was broken must be 
recorded in the source documentation and case report form, as a pplicable. 
Any unblinding of Sponsor personnel for expedited reporting of suspected unexpected serious 
adverse reactions (SUSARs) or other reasons will be addressed in a separate plan.  
6.4.2. Patient Enrollment and Study Drug Assignment 
It is the responsibility of the Investigator to ensure that patient eligibility is c onfirmed prior to 
randomization. Documentation of t he personally signed and dated informed consent of each 
patient, using the study-specific ICF, is required before initi ating the Screening Period.  
After written informed consent ha s been obtained, the patientâ€™s  identification number will be 
obtained from the IWRS. Once e ligibility to partic ipate has bee n established, the randomized 
treatment assignment will be  obtained from the IWRS. 
6.5. Study Drug Compliance 
Patients will be dispensed study during their study visits and will self-admin ister study drug at 
home. Compliance will be asse ssed  
 
   
 
 
 
 
 
 
6.6. Concomitant Therapy 
Any medication or vaccine (incl uding over-the-counter or prescr iption medicines, vitamins, 
and/or herbal supplements) that t he patient is receiving at the  time of randomiza tion or receives 
during the study must be record ed at each study visit along wit h: 
x Reason for use 
x Dates of administration including start and end dates 
x Dosage information inc luding dose and frequency 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 36 of 82     
 
 
 
 
  
 
 
 
  
 
 
 
 
Medications prohibited for use w ithin 3 months of randomization  and through the end of the 
study:  
x Medications with potential impact  on NASH outcome, including OC A, other 
investigational FXR agon ists, pioglitazone or other 33$5È–DJRQLVWV or high-dose vitamin 
E (> 400 IU/day).   
o 3DWLHQWVWUHDWHGZLWKYLWDPLQ(Â”,8GD\PXVWKDYHEHHQRQ VWDEOHGRVHIRUDW
least 3 months prior to screen ing and should remain on the same  dose during 
study.  
o Patients treated wit h GLP-1 analogues, D PP-4 inhibitors, and SG LT2 inhibitors 
must have been on a stable dose fo r at least 3 months prior to screening and 
should remain on the same dose during study. 
x Medications potentially impac ting steatohepatitis, including bu t not limited to systemic 
corticosteroids (prednisone e quivalent of > 10 mg/day for > 2 w eeks), amiodarone, 
tamoxifen and methotrexate. Use of systemic c orticosteroids for  < 2 weeks within 
3 months prior to randomization and while on study is allowed.  
  
 
 
  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 37 of 82   Medications allowed with steady use if initiated  at least 3 months before randomization, with 
expectation of no dose adjustment  during study participation:  
x Statins or PCSK9 inhibitors 
x Metformin and other di abetic drugs (must ha ve been on stable do se for at least 2 months 
before randomization). Note: GLP-1 analogues, DPP-4 inhibitors, and SGLT2 inhibitors 
addressed above.  
x Hormonal contraceptives 
The Medical Monitor should be contacted if there are any questi ons regarding concomitant 
therapy. Any dose adjustments that may be required during study participation should be discussed with the Medical Monitor. 
6.7. Dose Modifications 
Dose modifications of study drug are not permitted.  
6.8. Dose Interruptions 
On all non-study visit da ys, patients will self-administer the study drug orally once daily in the 
morning, without regard to food.  
 
  
  
 
 
 
  
 
 
 
6.8.1. Dose Interruptions due to COVID-19 
If a patient requires  home quarantine due t o SARS-CoV-2 infecti on or exposure, or due to 
COVID-19 symptoms, the patient  may continue study drug provided that appropriate safety 
follow-up is possible and that hos pitalization is not required.  Home health care visits may be 
made available to c ontinue study assessmen ts in the patientâ€™s h ome where feasible, and/or 
remote visits via telephone, telem edicine, or other appropriate  virtual communication may be 
substituted for a visit to the s ite. Sites should discuss the m echanism for safety follow-up with 
the Medical Monitor. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 38 of 82   If a patient has symptoms of COV ID-19 requiring hospitalization , study drug must be 
discontinued during hospitalizati on. A case-by-case assessment of whether to resume study drug 
can be done upon discharge. Dosi ng should not be resumed withou t consultation with the 
Medical Monitor. The patient s hould be encouraged to remain in the study to be evaluated during 
the Follow-Up Period.  
6.9. Intervention after the End of the Study 
No further interventions are planned after the end of the study .  
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 39 of 82   7. Discontinuation of Study Drug and Patient Discontinuation or 
Withdrawal 
7.1. Discontinuation of Study Drug 
  
  
 
  
  
  
 
  
  
  
   
  
 
 
 
  
  
 
 
   
  
  
 
 
  
 
 
If study drug is permanently discontinued, the patient will rem ain in the study to be evaluated 
during the Follow-Up Period. See the Schedule of Activities for  data to be collect ed at the time 
of discontinuation of study drug a nd follow-up and for any furt her evaluations that need to be 
completed. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 40 of 82   7.2. Patient Discontinuation/Withdrawal from the Study 
A patient may withdraw from th e study at any time  at his/her ow n request, or may be withdrawn 
at any time at the discretion of the inves tigator for safety, b ehavioral, compliance, or 
administrative reasons.  
 
 
 
 
 
 
 
7.3. Lost to Follow up 
A patient will be consid ered lost to follow-up if he or she rep eatedly fails to return for scheduled 
visits and is unable to be c ontacted by the study site. 
 
  
 
 
  
 
 
 
  
  
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 41 of 82   8. Study Assessments and Procedures 
Study procedures and their timing a re summarized in the Schedul e of Activities. Protocol 
waivers or exempti ons are not allowed. 
Adherence to the study design re quirements, including those spe cified in the Schedule of 
Activities, is essential and required f or study conduct. 
All screening evaluations must  be completed and reviewed to con firm that potential patients 
meet all eligibility criteria. The investigator will maintain a  screening log to rec ord details of all 
patients screened a nd to confirm eligib ility or record reasons for screening failure, as applicable. 
The maximum amount of blood coll ected from each patient over th e duration of the study is not 
expected to exceed 550 mL. Repeat  or unscheduled samples may be  taken for safety reasons or 
for technical issues  with the samples. 
If a patient requires  home quarantine due t o SARS-CoV-2 infecti on or exposure, or due to 
COVID-19 symptoms or other associated concern with attending an  in-person study visit, in 
accordance with Section 6.8.1, home health care visits may be m ade available to continue stu dy 
assessments in the patientâ€™s home where feasible, and/or remote  visits via telephone, 
telemedicine, or other appropria te virtual communication may be  substituted for a visit to the 
site. 
8.1. Study Assessments 
Planned time points for all safety assessments are provided in the Schedule of Activities.  
8.1.1. Demographics 
Demographic data includes ag e, sex, and race/ethnicity.  
8.1.2. Height and Weight 
Height and weight are collecte d at Screening and will be used t o calculate BMI for eligibility. 
Waist circumference is also measured at Screening. Only weight is collected at Weeks 0, 4, 6, 8, 
12, 16, and ET.   
 
 
 
 
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 42 of 82   8.1.3. Medical History 
Medical history, including details of  illnesses and allergies, date(s) of onset, whe ther condition(s) 
is currently ongoing, and medi cation history, including alcohol  use, will be collected for all 
patients at Screening.  
8.1.4. Physical Examinations 
A complete physical examination w ill include assessments of gen eral appearance, 
cardiovascular, respiratory, a bdomen, head and neck (including ears, eyes, nose and throat), 
lymph nodes, thyroid, and musculoskeletal systems.  
A targeted physical examination w ill be conducted to evaluate reported current or prior AEs, 
symptoms reported by the patient, or abnormal  laboratory readou ts.  
 
8.1.5. Vital Signs 
Temperature, pulse rate, respi ratory rate, and blood pressure w ill be assessed and maintained in 
source documentation.  Blood pressure and pulse measuremen ts will be assessed with a completely automated device. 
Manual techniques will be used onl y if an automated device is n ot available. 
Blood pressure and pulse measur ements should be preceded by at least 5 minutes of rest for the 
patient in a quiet setting without di stractions (eg, television , cell phones). 
8.1.6. Electrocardiograms 
Single 12-lead electrocardiograms (ECGs) will be obtained as ou tlined in the Schedule of 
Activities (see Section 1.3 ) using an ECG machine that autom atically calculates the heart rate 
and measures PR, QRS, and QT inte rvals. QTc will be calculated using the formula outlined in 
Appendix 4. 
 
 
 
  
8.1.7. Clinical Laborat ory Assessments 
See Appendix 1 for the list of clinical la boratory tests to be performed and to the Schedule of 
Activities for the timing and frequency. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 43 of 82   The investigator must review t he laboratory report, document th is review, and record any AEs 
per the guidance in Appendix 6. The laboratory reports must be filed with the  source document s.  
Shifts of clinically significant Grade 3 or Grade 4 laboratory abnormalities or a ny clinically 
significant laboratory abnormalities considered possibly relate d to study drug in the opinion of 
the investigator should be rep eated within 48-72 hours and followed to resolution or until stable. 
All protocol-required laborat ory assessments, as defined in Appendix 1, must be conducted in 
accordance with the laboratory manual and the Sch edule of Activ ities. 
8.1.7.1. Liver Function Tests 
In order to be eligible for his study, patients must have an $/7Â• 43 ,8/IRUPHQDQGÂ• 28 IU/L 
for women. ALT/AST stability may be  evaluated prior to randomization per Section 5 .  
During the course of the study, L FTs will be monitored per the Schedule of Activities. Refer to 
Appendix 1 for a list of tests  to be performed, and to Appendix 3 for additional information on 
criteria for increased liver chemistry monitoring. 
8.1.8. Transient Elastography  
Liver stiffness will be asse ssed by transient elastography at S creening to determine study 
eligibility. If results from tran sient elastography measurement  within 3 months of Screening are 
available, these v alues can be used to a ssess eligibility and d o not need to be repeated.  
 
 
  
8.1.9. MRI-PDFF  
MRI-PDFF will be conduc ted as specified in the  Schedule of Acti vities. 
Degree of liver steatosis will  be measured by MRI-PDFF at Scree ning. An MRI-PDFF may 
proceed on the basis of the initia l screening ALT/AST level, gi ven all other eligibility criteria are 
met, but randomization should not o ccur prior to confirmation o f ALT/AST stability as 
necessary, per Section 5 .  
An MRI-PDFF should be performed at ET only if not done within t he prior 4 weeks, and the 
patient has had at leas t 4 weeks of dosing.   
The images will be a nalyzed by a central reader. MRI-cT1 will b e collected along with MRI-
PDFF at sites with this capability,  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 44 of 82   8.2. Pharmacokinetics 
Plasma samples will be collected  for measurement of plasma conc entrations of study drug as 
specified in the Schedule of Activities and Appendix 2.  
Patients in the PK/PD sub-study will undergo intensive and trou gh PK sample collection as 
specified in the Schedule of Activities and Appendix 2.  
Patients who are not participa ting in the PK/PD sub-study will undergo trough PK sampling 
only, as specified in the Sch edule of Activities and Appendix 2 .  
Instructions for the collec tion and handling of biological samp les will be provided by the 
Sponsor. The actual date and time  (24-hour clock time) of each sample will be recorded. 
Samples will be used to evaluate the PK of study drug.  
 
Drug concentration informati on that may unblind the study will not be reported t o investigative 
sites or blinded personnel until the study has been unblinded. 
 
 
 
8.3. Pharmacodynamics 
Plasma samples will be collect ed for measurement of FGF19, 7- Ä®-C4,  as specified 
in the Schedule of  Activities and Appendix 2.  
 
Patients in the PK/PD sub-study will undergo intensive PD sampl e collection for FGF19 and 7-
Ä®-C4, and trough PD sample  collection for 7- Ä®-C4  as spec ified in the Schedule of 
Activities and Appendix 2 .  
Patients who are not participa ting in the PK/PD sub-study will undergo trough PD sampling only 
for 7-Ä®-C4  as specified i n the Schedule of Activities and Appendix 2.  
Instructions for the collec tion and handling of biological samp les will be provided by the 
Sponsor. The actual date and time  (24-hour clock time) of each sample will be recorded. 
Samples will be used to evaluate the pharm acodynamics of study drug.  
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 45 of 82    
 
 
8.4. Biomarkers 
Collection of samples for biomar kers related to NASH is also pa rt of this study. The following 
samples will be collected from all patients in this study as sp ecified in the Schedule of Activities:  
x Blood collection for the follo wing biomarkers: CK-18 (M30 and M 65), PIIINP, TIMP-1, 
HA, Pro-C3,  
 
 
 
 
 
 
 
 
 
8.5. Adverse Events and Serious Adverse Events 
An AE is any untoward medical occu rrence in a patient or clinic al study patient, temporally 
associated with the use of st udy drug, whether or not considere d related to the study drug.  
An SAE is defined as any untowar d medical occurrence that, at a ny dose, results in the 
following: death; is life threatening; requires in-patient hosp italization; results in persistent 
disability or incapacity; is a c ongenital anomaly or birth defe ct; or is a medicall y important event 
or reaction that ma y not be immediately life-threatening or result in death or hospitalization but 
may jeopardize the pa tient or may require m edical or surgical i ntervention to prevent one of the 
other outcomes in the definition.  
Events meeting the definition of  an AE or SAE are defined in Appendix 6, including details on 
recording, reporting, and follow- up of AEs and SAEs, assessment  of intensity, and assessment of 
causality. AEs will be reported by t he patient (or , when appropriate, by a caregiver, surrogate, or 
the patient's legally authorize d representative) at every study  visit. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 46 of 82   The investigator and any qualifie d designees are responsible for detecting, documenting, and 
recording events that meet t he definition of a n AE or SAE and r emain responsible for following 
up AEs that are serious, consid ered related to the study drug o r study procedures, or that caused 
the patient to disconti nue the study drug (see Section 7 ). 
8.5.1. Time Period and Frequency for Co llecting AE and SAE Information  
After informed consent but pr ior to initiation of study drug, t he following types of events should 
be reported: all AEs and SAEs related to pr otocol-mandated proc edures.  
Medical occurrences (events cons idered not related to protocol- mandated procedures) that begin 
before the start of study drug but after obtaining informed con sent will be recorded on the 
Medical History/Current Medi cal Conditions section of the eCRF not the AE section. 
All AEs and SAEs, regardless of cause or relationship, will be collected from the start of study 
drug through the Follow-Up Peri od, at every study visit, as spe cified in the Schedule of 
Activities ( Section 1.3 ). 
All SAEs will be recorded and reported to the Sponsor or design ee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 6 . The Investigator will 
submit any updated SAE data to the Sponsor within 24 hours of i t being available. 
Investigators are not obligated to actively seek reports of AEs or SAEs after conclusion of the 
study participation. However, if th e investigator learns of any  SAE, including a death, at any 
time after a patient has bee n discharged from the study, and he/she considers the event to be 
reasonably related to the st udy drug or study participation, th e investigator must promptly notify 
the Sponsor. 
8.5.2. Method of Detecting AEs and SAEs 
The method of recording, evalu ating, and assessing causality of  AEs and SAEs and the 
procedures for completing and t ransmitting SAE reports are provided in Appendix 6 . 
Care will be taken not to introdu ce bias when detecting AEs and /or SAEs. Open-ended and 
non-leading verbal questioning of t he patient is the preferred method to inquire about 
AE occurrences. 8.5.3. Follow-up of AEs and SAEs 
After the initial AE and/or SAE report, the investigator is req uired to proactively follow each 
patient at subsequent visits/contacts. All SAEs will be followe d until resolution, stabilization, the 
event is otherwise explained, or  the patient is lost to follow- up (as defined in Section 7.3 ). 
Further information on follow-up procedures is provided in Appendix 6 . 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 47 of 82   8.5.4. Regulatory Reporting R equirements for SAEs 
Prompt notification by the inves tigator to the Sponsor of a SAE  is essential so that legal 
obligations and ethical responsib ilities towards the safety of patients and the safety of a study 
drug under clinical investigation can be met. 
The Sponsor has a legal responsibility to notify both the local  regulatory authority and other 
regulatory agencies about the safety of a st udy drug under clin ical investigation. The Sponsor 
will comply with country-specific regulatory requirements relat ing to safety reporting to the 
regulatory authority, IRB/ IEC, and investigators. 
Investigator safety reports must be prepared for SUSARs accordi ng to local regulatory 
requirements and sponsor policy a nd forwarded to investigators as necessary. 
An investigator who receives an investigator safety report desc ribing a SAE or other specific 
safety information (e g, summary or listing of SAEs) from the sp onsor will review and then file it 
along with the Investigatorâ€™s B rochure and will notify the IRB/ IEC, if appropriate according to 
local requirements. 
8.5.5. Pregnancy 
 
 
 
 
 
8.5.6. Assessment of Pruritus 
For patients who report AEs c onsistent with pruritus, photograp hs of the affected area(s) will be 
taken at the discreti on of the Investigator (eg, if there are v isible skin lesions; photos that would 
identify the patient, i e, of the entire face, will be avoided), and a qualified s taff member will 
administer the Pruritus N umerical Ra ting Scale ( Appendix 8) at each study visit where pruritus is 
reported or noted to be ongoing. If pruritus is reported, the c linical site will  provide details on 
these events in the eCRF.  
The Investigator will be asked t o provide an asse ssment of the severity of the A E using the NCI 
CTCAE v5.0 categories for  pruritus as follows:  
x Grade 1: Mild or localized; t opical interven tion indicated.  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 48 of 82   x Grade 2: Widespread and intermittent; skin changes from scratch ing (eg, edema, 
papulation, excoriations, lichenification, oozing/crusts); oral  intervention indicated; 
limiting instrumental activitie s of daily living (ADL).  
x Grade 3: Widespread and consta nt; limiting self-care, ADL, or sleep; systemic 
corticosteroid or immunos uppressive therapy indicated. 
 
For Grade 3 cases, follow up by telephone contact or in person visit should occur within 3 days 
or at the discretion of the Inv estigator. Additional follow up may take place until symptoms 
improve. Refer to Section 7  for additional informa tion on study drug discontinuation.   
  
 
 
 
 
 
 
 
  
 
 
  
   

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 51 of 82   The baseline value is defined to be  the latest assessment value  prior to the first dose of study 
drug, unless specified in the SAP for some particular tests. 
Missing values will not be imputed. 
Data analysis will be perfor med using SASÂ® Version 9.4 or highe r. 
SDTM (Study Data Tabulation Model)  and Analysis Data Model (ADa M) datasets will be 
prepared using Clinical Data Inte rchange Standards Consortium ( CDISC) SDTM IG Version 3.2, 
ADaM Version 2.1, and CDISC ADaM Im plementation Guide Version 1 .1.  
9.4.2. Primary Endpoints 
Safety parameters w ill be listed and summa rized using descripti ve statistics. The safety 
parameters will include AEs, and treatment emergent clinical la boratory parameters. No formal 
statistical testing is planned.  Reported AEs will be coded using the latest  version of Medical Dictionary for Regulatory 
Activities (MedDRA Version 22.1, or most recent) and graded for  severity according to NCI 
CTCAE, Version 5.0.  All TEAEs will be listed and su mmarized by MedDRA Preferred Ter m and System Organ Class, 
as well as by maximum intensity and study drug causality, in fr equency and percentage. 
Summaries of treatment-emergent SAEs, TEAEs related to study dr ug, TEAEs resulting in study 
drug discontinuations a nd death will be produced. 
Grade shifts in laboratory tests will be summarized in addition  to AEs. Absolute or relative 
changes from baseline  of quantitative measur ements will be anal yzed by treatment group and 
timepoints and presented in shift tables, if applicable. Labora tory abnormalities will be graded 
according to NCI CTCAE Version 5.0.  The number and percentage of subj ects experiencing treatment-em ergent graded lab toxicities 
will be summarized by treatme nt group and severity grade.  
Further details on the analysis  of safety parameters will be pr ovided in the SAP. 
9.4.3.  Secondary Endpoints 
9.4.3.1. Change from Baseline in ALT Levels at 12 Weeks 
The secondary efficacy variable is the percent change from Base line in the ALT after 12 weeks 
of treatment in patients treated with either TERN-101 or matchi ng placebo. The mean percent 
change from baseline in ALT in each TERN-101 group will be comp ared with placebo 
separately without controlling for  any family-wise error rate ( overall type I error) by using 
analysis of covariance (ANCOVA)  methods. The percent change fro m baseline in ALT will also 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 53 of 82   For the Intensive PD sampling sub-study an ANOVA model will be fit with change from 
baseline as response variable, a nd baseline value and treatment  as fixed effects. 
x Change from baseline in FGF-19 and 7- Ä®-C4  
x Change from baseline in NASH/fibrosis biomarkers  
 
 
 
 
 
 
MRI-cT1  will be addressed in the SAP. 
9.4.4.1. PD Endpoints 
 
No formal statis tical analysis of PD data is 
planned, however, data m ay be used for statistical analysis or modeling to evaluate correlation of 
PK and PD parameters, if applicable. These analyses will be def ined in the SAP. 
   
 
  

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 54 of 82   10. Regulatory, Ethical, and Study Oversight Considerations 
10.1. Regulatory and Ethical Considerations 
This study will be conduc ted in accordance w ith the protocol an d with the following: 
x Consensus ethical prin ciples derived from international guideli nes including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) Internationa l Ethical Guidelines 
x Applicable International Counc il on Harmonisation (ICH) Good Cl inical Practice (GCP) 
Guidelines 
x Applicable laws and regulations 
The protocol, protocol amendments , ICF, Investigator Brochure, and other relevant documents 
(eg., advertisements) must be s ubmitted to an IRB/IEC by the in vestigator and reviewed and 
approved by the IRB/IEC before  the study is initiated. 
Any amendments to the protocol w ill require IRB/IEC approval be fore implementation of 
changes made to the study design, e xcept for changes necessary to eliminate an immediate 
hazard to study patients. 
The investigator will be res ponsible for the following: 
x Providing written summaries of the status of the study to the I RB/IEC annually or more 
frequently in accordance with the  requirements , policies, and p rocedures established by 
the IRB/IEC 
x Notifying the IRB/IEC of SAEs or  other significant safety findi ngs as required by 
IRB/IEC procedures 
x Providing oversight of the conduct of the study at the site and  adherence to requirements 
of 21 Code of Federal Regulations  (CFR), ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical st udies (if applicable), and a ll other applicable local 
regulations 
10.1.1. Financial Disclosure 
Investigators and sub-investigat ors will provide the sponsor wi th sufficient, accurate financial 
information as requested to allo w the sponsor to submit complet e and accurate financial 
certification or disclosure state ments to the appropriate regul atory authorities. Investigators are 
responsible for providing information on financial interests du ring the course of the study and for 
1 year after completion of the study. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 55 of 82   10.1.2. Informed Consent Process 
The investigator or his/her representative will explain the nature of the study to the patient or 
his/her legally authorized repre sentative and answer all questions regarding the study. 
Patients must be infor med that their partic ipation is voluntary . Patients or their l egally authorized 
representative will be required t o sign a statement of informed  consent that meets the 
requirements of 21 CFR 50, local r egulations, ICH guidelines, H ealth Insurance Portability and 
Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
The medical record must include a statement that written inform ed consent was obtained before 
the patient was enrolled in the  study and the date  the written consent was obtained. The 
authorized person obtaining the inf ormed consent must also sign  the ICF. 
Patients must be re-consented to the most current version of th e ICF(s) during the ir participation 
in the study. 
A copy of the ICF(s) must be provided to the patient or the pat ientâ€™s legally authorized 
representative. The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for optional exploratory res earch for up to 15 years after the end of the study. The investigator or 
authorized designee will explain to each patient the objectives  of the exploratory research. 
Patients will be told that they are free to refuse to participa te and may withdraw t heir consent at 
any time and for any reason during t he storage period. A separa te signature will be required to 
document a patient's agreement to allow any remaining specimens  to be used for exploratory 
research. Patients w ho decline to participate in this optional research will not provide this 
separate signature. Written informed consent may be  obtained via telephone with app ropriate documentation of how 
the informed consent form was transmitted to the patient, (such  as via email, fax, or mail) and 
how signature was obtained. Scr eening may be initiated via tele phone to avoid a visit to the site 
if the patient is disqualif ied based on medical history. 
10.1.3. Data Protection 
Patients will be assi gned a unique identifier by the sponsor. A ny patient records or  datasets that 
are transferred to the sponsor w ill contain the identifier only ; patient names or  any information 
which would make the patient ide ntifiable will not be transferr ed. 
The patient must be informed that his/her  personal study-relate d data will be used by the sponsor 
in accordance with lo cal data protection law. The level of disc losure must also be explained to 
the patient who will be  required to give consent for their data  to be used as de scribed in the 
informed consent.  
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 56 of 82   The patient must be informed that his/her medical records may b e examined by Clinical Quality 
Assurance auditors or other au thorized personnel appointed by t he sponsor, by appropriate 
IRB/IEC members, and by inspect ors from regulatory authorities.  
10.1.4. Dissemination of Clinical Study Data 
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies) by 
Terns, Inc, as appropriate. Terns, Inc. will ensure that the re port meets the standards set out in the 
ICH Guideline for Structure a nd Content of Clinical Study Repor ts (ICH E3). Note that an 
abbreviated report ma y be prepared in certain cases. Public dis closure of study results will be in 
accordance with all applicable l aws and ICH guidelines. The pos ting of company-sponsored 
study information and tabular st udy results on the US National Institutes of Healthâ€™s website 
www.ClinTrials.gov and other pub licly accessible sites. 
10.1.5. Data Quality Assurance 
All patient data rel ating to the study w ill be recorded on prin ted or electronic CRF unless 
transmitted to the sponsor or desi gnee electronically (eg, labo ratory data). The investigator is 
responsible for verifying that da ta entries are accurate and co rrect by physically or electronically 
signing the CRF. 
The investigator must maintai n accurate documentation (source d ata) that supports the 
information entered in the eCRF. The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide  direct access to source data doc uments. 
Monitoring details describing str ategy (eg, risk- based initiati ves in operations and quality such as 
Risk Management and Mitigation Str ategies and Analytical Risk-Based Monitoring), methods, 
responsibilities and r equirements, inc luding handling of noncom pliance issues and monitoring 
techniques (central, remote, or  on-site monitori ng) are available in the Monitoring Plan and site-
specific contracts.  The sponsor or designee is respons ible for the data management of this study including quality 
checking of the data. The sponsor assumes accountability for actions delegated to other individuals (eg, Contract 
Research Organizations). 
Study monitors will perform ongoing s ource data verification to  confirm that data entered into 
the eCRF by authorize d site personnel are accurate, complete, and verifiable from source 
documents; that the safety and r ights of patients are being pro tected; and that the study is being 
conducted in accordance with the c urrently approved protocol an d any other study agreements, 
ICH GCP, and all applicable  regulatory requirements. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 57 of 82   Records and documents, includi ng signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator until at least 2 years after the l ast approval of a marketing application 
in an ICH region (ie, United Sta tes, Europe, or Japan) and unti l there are no pending or 
contemplated marketing applica tions in an ICH region (ie, Unite d States, Europe, or Japan) or at 
least 2 years have elapsed since the formal discontinuation of clinical development of the 
investigational produc t. These documents should be retained for  a longer period however if 
required by the applicable regulat ory requirement(s) or if need ed by the sponsor. No records may 
be destroyed during the retenti on period without t he written ap proval of the sponsor. No records 
may be transferred to another l ocation or party without written  notification to the sponsor. 
10.1.6. Protocol Deviations 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitte d. In the event of a significant de viation related to 
gross non-compliance from the prot ocol, or events that impose significant risk to patient safety, 
the investigator or designee must notify the Sponsor or designe e immediately. Deviations must 
be documented in accordance wit h the Sponsorâ€™s procedures, and in accordance with any site 
procedures or processes.  
10.1.7. Source Documents 
Source documents provide evidence for the existence of the pati ent and substantiate  the integrity 
of the data collected. Source docu ments are stored at the inves tigatorâ€™s site. 
Data reported on the eCRF or entered in the eCRF that are trans cribed from source documents 
must be consistent with the source  documents or the discrepanci es must be explained. The 
investigator may need to request  previous medical records or tr ansfer records, depending on the 
study.  
The required source data should i nclude notes containing at lea st the following information for 
each patient:  
x Patient identification ( name, date of birth, gender) 
x Documentation that the patie nt meets eligibility criteria 
x Documentation of the reason(s) a consented patie nt is not enrol led 
x Participation in st udy (including study number) 
x Study discussed and date of  informed consent 
x Dates of all visits 
x Documentation that protocol speci fic procedures were performed 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 58 of 82   x Results of efficacy parameters , as required by the protocol 
x Start and end date (including dose regimen) of study drug admin istration, including dates 
of dispensation and return as applicable 
x Record of all adverse events and other safety parameters (start  and end date, and 
including causality and severity) 
x Concomitant medication (incl uding start and end date, dose if r elevant; dose changes) 
x Date of study completion and r eason for early discontinuation, if applicable  
10.1.8. Study and Site Start and Closure 
The first patient screened is c onsidered the first act of recruitment and will be the study start 
date. 
The sponsor or designee reserves  the right to close the study s ite or terminate the study at any 
time for any reason at the sole discretion of  the sponsor. Study sites will be closed upon study 
completion. A study site is consid ered closed when all required  documents and study supplies 
have been collected and a study-s ite closure visit has been per formed. 
The investigator may initiate s tudy-site closu re at any time, p rovided there is reasonable cause 
and sufficient notice is given i n advance of the  intended termi nation. 
Reasons for the early closu re of a study site by the sponsor or  investigator ma y include but are 
not limited to: 
x Failure of the investigator to comply with the protocol, the re quirements of the IRB/IEC 
or local health authorities, t he sponsor's procedures, or GCP guidelines 
x Inadequate recruitment of pa tients by the investigator 
x Discontinuation of furth er study drug development 
If the study is prematurely termin ated or suspended, the sponso r shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory a uthorities, and a ny contract research 
organization(s) used i n the study of the reason for termination  or suspension, as specified by the 
applicable regulatory requireme nts. The Investigator shall promptly inform the subject and 
should assure appropriate follo w-up care as warranted by the protocol or as medically necessary. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 60 of 82   Total Cholesterol 
Triglycerides  VLDL 
Urinalysis x Specific gravity 
x pH, glucose, protein, blood, ke tones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by dipstick 
x Microscopic examination (if  blood or protein is abnormal) 
   
Other Tests x  
x Blood alcohol test1 
x Urine drug screen including amphe tamines, barbiturates, cocaine , 
opiates, cannabinoids a nd benzodiazepines 
x Serology1: HIV antibody, HBsAg, and HCV antibody6 
x COVID-19: SARS-CoV-2 test for active infection (e.g. molecular test 
such as PCR or viral antigen serology), and SARS-CoV-2 Ab test (IgG 
and IgM) 
NOTES: 
1 Only collected at Screening.  
2 Details of liver chemistry increased monitoring criteria are gi ven in Appendix 3.  
3 eGFR to be calculated by  central lab; refer to Appendix 5 for the formula. 
4 If total bilirubin is increased above the upper limit of normal  there should be a reflex to direct and indirect 
bilirubin, as outlined in Appendix 3 . 
5 At Screening, Week 0, and if significant abnormal liver function is observed, as outlined in Appendix 3 . 
6 If HCV antibody positive, conduct HCV RNA test.   
Abbreviations:   È•-hCG = È•-human chorionic gonadotropin; ALP = alkaline phosphatase; ALT = alanine 
transaminase; AST = aspartate transaminase; BUN = blood urea nitrogen; CPK = creatine phosphokinase; eGFR = 
estimated glomerular filtration rate; FSH = Follicle-stimulatin g hormone GGT = gamma-glutamyl transpeptidase; 
HbA1c = hemoglobin A1c; HBsAG = hepatitis B surface antigen; HC G = human chorionic gonadotropin; HCV = 
hepatitis C virus; HDL = high-density lipoprotein; HIV = human immunodeficiency virus; IgG = immunoglobulin G; IgM = immunoglobulin M; LDL = low-density lipoprotein; MCH =  mean corpuscular hemoglobin; MCV = 
mean corpuscular volume; PCR = polymerase chain reaction; RBC =  red blood cell; RNA = ribonucleic acid; 
SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2; V LDL = very low-density lipoprotein; WBC 
= white blood cell; WOCBP = women of childbearing potential 
Investigators must document thei r review of each laboratory safety report. Shifts of clinically 
significant Grade 3 or Grade  4 laboratory abnor malities or any clinically signifi cant laboratory 
abnormalities considered possibl y related to study drug in the opinion of the investigator should 
be repeated within 48-72 hours a nd followed to resolution or un til stable. 
Laboratory/analyte results that could unblind the study will no t be reported to investigative sites 
or other blinded personnel un til the study has been unblinded. 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 63 of 82   Appendix 4: Fridericiaâ€™s Formula 
A single 12-lead ECG will be obtained as outlined in the Schedu le of Activities (see Section 1.3) 
using an ECG machine that automa tically calculates the heart ra te and measures PR, QRS, and 
QT intervals. QTc will be calcula ted using Fredericiaâ€™s Formula  as outlined below.  
The Investigator will review the  ECGs for any clinically significant abnormalities.  
Fridericiaâ€™s Formula:  
QTc = QT/(RR^0.33) http://www.thecalculator.co/health/QTc-Calculator-385.html  
 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 64 of 82   Appendix 5: Chronic Kidney Disease Epidemiology Collaboration ( CKD-EPI) 
Formula to Estimate Glomerular Filtration Rate  
 
GFR = 141 Ã— min(S crÈ›Ä® Ã— max(S crÈ›-1.209 Ã— 0.993Age Ã— 1.018 [if female] Ã— 1.159 [if black] 
 
Abbreviations / Units:  
SCr (standardized serum creatinine) = mg/dL È› IHPDOHVRUPDOHV  
Ä® -0.329 (females) or -0.411 (males) 
PLQ LQGLFDWHVWKHPLQLPXPRI6&UÈ›RU  
PD[ LQGLFDWHVWKHPD[LPXPRI6&UÈ›RU  
age = years
 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 71 of 82    
 
 
 
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 73 of 82    
 
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
CONFIDENTIAL Page 74 of 82  Appendix 8: Pruritus Numerical Rating Scale 
This Numerical Rati ng Scale was adapted from IFSI SIG/EADV Task  Force Pruritus 
assessments available at http://www.pruritussymposium.de/numericalratingscale.html . 
 

Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 75 of 82   Appendix 9: COVID-19 Assessments 
At Screening:  
x SARS-CoV-2 testing to assess for active infection (e.g. molecular test such as polymerase 
chain reaction [PCR] or viral a ntigen serology) and past infect ion (Immunoglobulin G 
[IgG] antibody required; Immunogl obulin M [IgM] antibody recommended in addition).  
x Prior to central laboratory testing availability, antibody testing may be omitted if not 
available locally. 
At Week 0, 6, and 12:  
x Testing for past infection via antibody testing (IgG required; IgM recommended in 
addition) if prior IgG was negative.  
x Prior to central laboratory testing availability , testing for a ctive infection (e.g. molecular 
test such as PCR or viral antig en serology) may replace antibod y testing if the latter is not 
available locally. 
x If Week 0 occurs within 2 weeks of Screening, site may omit repeat SARS-CoV-2 testing at PI discretion. 
x If IgM antibody test is positive, m ay reflex to test for SARS-C oV-2 active infection at 
Investigatorâ€™s discretion 
Ad-hoc:  
x In the event of symptoms sugge stive of COVID-19, ad hoc testing  (including molecular 
test such as PCR or viral antigen serology, and/or antibody tes ting, once available via the 
central laboratory), may be comp leted at Investigatorâ€™s discret ion. 
Sites may use local laboratory testing for COVID-19 assessments  instead of central laboratory, 
per site preference. If a local l aboratory is used, the results  must be entered into the eCRF. 
Results from previous testing m ay be used if completed within 2  weeks of a scheduled Screening 
or on-study visit. 
Any positive tests reflecting ac tive or recent infection (e.g. molecular test such as PCR or viral 
antigen serology, or IgM antibody) r equire management per local  public health guidelines, at the 
direction of the investigator. If technological changes result in changes to the assays implemented to assess for SARS-CoV-2, 
available central lab assays a nd testing mechanisms may change.  
The testing approach and sche dule may be modified based on the evolving landscape of the 
pandemic or in response to local public health requirements. In  that event, regulatory 
requirements, IRB requirements , and local institutional guideli nes will be followe d, as necessary. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 76 of 82   Appendix 10: Abbreviations 
Abbreviation or 
Special Term Explanation 
7-Ä®-C4 Ä®-hydroxy-4-cholesten-3-one 
È•-hCG Human chorionic gonadotropin 
ADaM  Analysis Data Model 
ADL  Activities of Daily Living 
AE Adverse event 
ALP Alkaline phosphatase 
ALT Alanine transaminase  
ANCOVA Analysis of covariance  
AST Aspartate transaminase 
AUC  Area under the concentration-time curve 
BMI Body mass index 
BUN Biliary urea nitrogen 
CAP Controlled attenuation parameter 
CDISC Clinical Data Interchange Standards Consortium 
CFR Code of Federal Regulations  
CIOMS Council for International Organizations of Medical Scienc es 
COVID-19 Coronavirus disease 2019 
CPK Creatinine phosphokinase  
CONSORT Consolidated Standards of Reporting Trials 
Cmax Maximal concentration 
CRF 
CSR Case report form 
Clinical study report  
CTCAE Common Terminology Criteria for Adverse Events  
CYP Cytochrome P450  
CV Coefficient of variation  
DBL Database lock 
eGFR Estimated glomerular filtration rate 
eCRF Electronic case report form 
ECG Electrocardiographic 
ET Early Termination 
FAS Full Analysis Set 
FDA Food and Drug Administration 
FGF Fibroblast growth factor 
FSH Follicle stimulating hormone 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 77 of 82   Abbreviation or 
Special Term Explanation 
FXR  Farnesoid X receptor 
GCP Good clinical practice 
GGT  Gamma-glutamyl transpeptidase 
HBsAG Hepatitis B virus surface antigen 
HCV  Hepatitis C virus 
HDL  High-density lipoprotein 
HIV Human immunodeficiency virus 
HIPAA Health Insurance Portability and Accountability Act 
HRT Hormone replacement therapy 
ICF Informed consent form 
ICH International Council on Harmonisation 
IEC Independent Ethics Committee 
IND Investigational new drug 
INR International normalized ratio 
IRB Institutional Review Board 
IUD Intrauterine device 
IUS Intrauterine hormone-releasing system 
IWRS Interactive web response system 
LAM lactational amenorrhoea method 
LDL  Low-density lipoprotein   
LDLR  Low-density lipoprotein receptor  
LFC Liver fat content 
LFT Liver function test 
MCH Mean corpuscular hemoglobin 
MCV Mean corpuscular volume 
MedDRA  Medical Dictionary for Regulatory Activities 
MRI-PDFF  Magnetic Resonance Imaging Proton Density Fat Fraction  
mpk mg/kg 
NAFLD Non-alcoholic fatty liver disease 
NAS  Non-alcoholic fatty liver disease activity score 
NASH Non-alcoholic Steatohepatitis 
NCI National Cancer Institute 
NHP Nonhuman primate 
NOAEL  No observed adverse effect level 
OCA  Obeticholic acid 
PCR Polymerase chain reaction 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 78 of 82   Abbreviation or 
Special Term Explanation 
PD Pharmacodynamics 
PK Pharmacokinetics 
po Per os (oral) 
QD Once daily 
RBC Red blood cell 
RNA Ribonucleic acid 
SAE Serious adverse event 
SAP Statistical analysis plan 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 
SCr Standardized s erum creatinine 
SD Sprague Dawley 
SoA Schedule of Activities 
SUSAR Suspected unexpected serious adverse reactions 
TEAE Treatment emergent adverse event 
TERN-101 An investigational agonist of Farnesoid X receptor 
US United States  
VLDL Very low-density lipoprotein 
WBC White blood cell 
WOCBP Women of child bearing potential 
  
 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 79 of 82   Appendix 11: Investiga tor Signature Page 
Protocol Title: A Multicenter , Randomized, Double-Blind, Placebo-Controlled, P arallel-Group, 
Phase 2a Clinical Trial to Ev aluate the Safety, Tolerability, E fficacy, and Pharmacokinetics of 
Orally Administered TERN-101 Tab lets in Adult Patients with Pre sumed Non-Cirrhotic Non-
Alcoholic Steatohepatitis (NASH) 
Protocol Number:   TERN101-2001 Protocol Version/Date :  Amendment 1; 22 May 2020 
 I confirm that I have read the  above-mentioned protocol and its attachments. I agree to conduct 
the described trial in complian ce with all stipulations of the protocol, regulations and ICH E6 
Guideline for Good Clinical Pr actice (GCP). I will provide all study personnel under my 
supervision copies of the protocol and access t o all informatio n provided by Terns, Inc. I will 
discuss this material with them to ensure that they are fully informed about the study drug and 
the study. 
____________________________________ Principal Investigator Name (Printed)   ____________________________________ Signature   
____________________________________ Date   
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 80 of 82   Appendix 12: Protoco l Amendment History 
This document (dated 22 May 2020) i s Amendment 1, the document history is below. The 
Summary of Changes for each ame ndment listed below will be prov ided separately. 
DOCUMENT HISTORY 
Document Date 
Amendment 1 22-May-2020 
Original 26-Feb-2020 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 81 of 82   Appendix 13: References 
Andronescu CI, Purcarea MR, Babe s PA. Nonalcoholic fatty liver disease: epidemiology, 
pathogenesis and thera peutic implications. J Med Life . 2018;11(1):20â€“23. 
Cariou B and Staels B. FXR: A Pro mising Target for the Metabolic Syndrome? Trends in Pharm 
Sci. 2007;28:236-243. 
Chalasani N, Younossi Z,2 Lavine JE, Charlton M, Cusi K, Rinell a M, Harrison SA, Brunt EM, 
and Sanyal AJ. The Diagnosis and  Management of Nonalcoholic Fat ty Liver Disease: Practice 
Guidance from the American Associ ation for the Study of Liver D iseases. Hepatol. 2018;67:328-
57. Dietrich P, Hellerbrand C. Non-al choholicalcoholic Fatty LiverL iver Disease, Obesity, and the 
Metabolic Syndrome. Best Pract and Res. 2014;28:637-53. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S et al. Fibrosis Stage is the 
Strongest Predictor for Disease- specific Mortality in NAFLD After up to 33 years of Follow-up. 
Hepatology. 2015;61:1547-54. Enanta Pharmaceuticals. Pre ss Release. 25 September 2019. 
Fiorucci S, Rizzo G, Donini A , Distrutti E and Santucci L. 2007. Targeting Farnesoid X Receptor 
for Liver and Metabolic Disor ders. Trends in Mol Med. 2007;13:298-309. 
Harrison SA, Bashir MR, Shim-Lopen J, Son K, Chen HC. MET409, a  susatained FXR agonist, 
decreased hepatic fat and impr oved liver function without raisi ng LDL-C after 28 days in NASH 
patients. Paris NASH Meeting; Jul y 2019; poster presentation.  
Houten SM, Watanabe M, and Auwerx  J. Endocrine Functions of Bil e Acids. EMBO J 
2006;25:1419â€“1425. Kalaany NY and Mangelsdorf DJ. LXRS and FXR: The Yin and Yang of Cholesterol and Fat 
Metabolism Annu. Rev Physiol. 2006;68:159â€“191. 
Lee FY, Lee H, Hubbert ML, Edwar ds PA and Zhang Y. FXR, a Multipurpose Nuclear Receptor. 
Trends Biochem Sci. 2006;31:572â€“580. 
Lonardo A, Nascimbeni F, Mant ovani A, Targher G. Hypertension, diabetes, atherosclerosis and 
NASH: cause or consequenc e? J Hepatol. 2018;68:335-352. 
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull  MV, Lustig KD, 
Mangelsdorf DJ and Shan B. Identification of a Nuclear Receptor  f o r  B i l e  A c i d s .   S c i e n c e .  
1999;284:1362-1365. 
Protocol TERN101-2001 
Terns, Inc. Version: Amendment 1 
Version Date: 22 May 2020 
 
CONFIDENTIAL Page 82 of 82   Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marscall H-U, Kipnes  M, et al. Efficacy and 
Safety of the Farnesoid X Recep tor Agonist Obeticholic Acid in Patients with T ype 2 Diabetes 
and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;14 5:574-582. 
National Heart, Lung, and Blood Ins titute. The Practical Guide: Identification, Evaluation, and 
Treatment of Overweight and Obes ity in Adults. US Department of  Health and Human Services, 
Public Health Service , National Institutes  of Health, National Heart Lung and Blood Institute, 
Bethesda, MD, October 2000. Accessed on 29 January 220 at 
https://www.nhlbi.nih.gov/files/ docs/guidelines/prctgd_c.pdf. 
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., 
Abdelmalek, M. F., et al. Farneso id X Nuclear Receptor Ligand O beticholic Acid for Non-
cirrhotic, Non-alcoholic steatohepatitis (FLINT): a Multicentre , Randomised, Placebo-controlled 
Trial. Lancet. 2015;385,956â€“965. 
Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Klie wer SA, Stimmel JB, Willson 
TM, Zavacki AM, Moore DD and Lehm ann JM. Bile Acids: Natural Li gands for an Orphan 
Nuclear Receptor. Science. 1999;284:1365-1368. 
Rader DJ.  Liver X Receptor and Farnesoid X Receptor as Therape utic Targets. Am J Cardiol. 
2007;100[Suppl]:15Nâ€“19N. 
Sanyal A, Lopez P, Lawitz E, Kim W, Huang JF, Andreone P, et al . Tropifexor (TXR), an FXR 
agonist for the treatment of NASH - interim results from first two parts of Phase 2b Study 
FLIGHT-FXR. American Association for the Study of Liver Disease s Annual Meeting; San 
Francisco, CA; November 2018; Abstract 168. 
Wang K and Wan YJ. Nuclear Receptors and Inflammatory Diseases.  Exp Biol Med. 
2008;233:496â€“506. 
Wang H, Chen J, Hollister K, Sowers LC, and Forman BM. Endogeno us Bile Acids Are Ligands 
for the Nuclear Receptor FX R/BAR. Mol Cell. 1999;3:543-553. 
Wong RJ, Aguilar M, Cheung R, P erumpail RB, Harrison SA, Younos s i  Z M ,  A h m e d  A .  
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting 
liver transplantation in the Un ited States. Gas troenterol. 2015;148: 547-55. 
Younossi ZM, Raziu V, Loomba R, Rinella M, Anstee QM, Goodman Z  et al. Obeticholic acid for 
the treatment of non-alcoholic s teatohepatitis: interim analysi s from a multicenter, randomized, 
placebo-controlled phase 3 t rial. Lancet. 2019;394:2184-96. 
Zhang Y and Edwards PA. FXR Signaling in Metabolic Disease. FEB S Lett. 2008;582:10-18. 
 